<DOC>
	<DOCNO>NCT00125190</DOCNO>
	<brief_summary>This study intend assess effect daily dose recombinant human insulin-like growth factor ( rhIGF-1 ) increase height velocity .</brief_summary>
	<brief_title>Recombinant Human Insulin-Like Growth Factor ( rhIGF-1 ) Treatment Short Stature Associated With IGF-1 Deficiency</brief_title>
	<detailed_description>Growth failure associate primary IGF-1 deficiency ( IGFD ) . Primary IGFD term use describe patient intrinsic cellular defect growth hormone ( GH ) action . In protocol , primary IGFD define short stature ( &lt; -2 standard deviation [ SDs ] mean age gender ) , abnormal serum IGF-1 ( &lt; -2 SDs mean age gender ) . The trial open-label , concentration-controlled trial conduct 20 center throughout United States .</detailed_description>
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Growth Disorders</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Chronological age ≥ 3 Chronological age bone age ≤ 12 boy ≤ 11 girl Prepubertal Visit 1 Height SD score &lt; 2 IGF1 SD score &lt; 2 Prior treatment GH , IGF1 , growthinfluencing medication Growth failure associate identifiable cause ( e.g. , syndrome , chromosomal abnormality ) Chronic illness diabetes , cystic fibrosis , etc .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Primary IGF-1 Deficiency</keyword>
	<keyword>IGF-1</keyword>
</DOC>